chevron_leftBack
As of 9 June 2026, Sun Pharma Advanced Research Company Ltd. has a market cap of $505.52M USD, ranking #15045 globally and #810 in India.
It ranks #1339 in the Healthcare sector, and #491 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$505.52MUSD
48.21B INR
Enterprise Value
$549.02MUSD
52.37B INR
Revenue (TTM)
$5.57MUSD
531.36M INR
EBITDA (TTM)
-$23.95MUSD
-2.28B INR
Net Income (TTM)
-$28.09MUSD
-2.68B INR
PS Ratio
90.7
PB Ratio
-14.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Anilkumar Raghavan
open_in_new
Employees
316
Founded
2006
Website
sparc.life
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.7% | 4.5% | 24% | 19% | 8.4% | 0.6% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SPARC
Sun Pharma Advanced Research Co Ltd
ISIN: INE232I01014
Shares Out.:
Shares Outstanding:
324.522M1
Shares Float:
87.908M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
143.04 INR | |
|
532872
(SPARC)
Sun Pharma Advanced Research Co Ltd
ISIN: INE232I01014
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
148.35 INR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Sun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NSE: SUNPHARMA
|
$44.75B
9K%
4.27T INR
|
39.1
|
|
NSE: DIVISLAB
|
$18.19B
3K%
1.73T INR
|
70.0
|
|
NSE: TORNTPHARM
|
$15.01B
3K%
1.43T INR
|
63.0
|
|
NSE: DRREDDY
|
$11.61B
2K%
1.11T INR
|
19.6
|
|
NSE: MANKIND
|
$9.77B
2K%
931.67B INR
|
52.2
|
|
NSE: ZYDUSLIFE
|
$9.61B
2K%
916.53B INR
|
18.6
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
151K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
108K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
71K%
|
97.4
|
|
SIX: RO
|
$322.98B
64K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.68B
57K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$275.9B
54K%
218.9B CHF
|
20.5
|
chevron_leftBack